BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38400840)

  • 1. Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy.
    Abdel-Wahab N; Suarez-Almazor ME
    Expert Rev Clin Immunol; 2024 Mar; ():1-21. PubMed ID: 38400840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis.
    Zhang S; Zhou Z; Wang L; Li M; Zhang F; Zeng X
    Ther Adv Chronic Dis; 2021; 12():2040622320976996. PubMed ID: 33633822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy.
    Shen P; Deng X; Hu Z; Chen Z; Huang Y; Wang K; Qin K; Huang Y; Ba X; Yan J; Han L; Tu S
    Front Med (Lausanne); 2021; 8():762247. PubMed ID: 34805229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)].
    Tingry T; Massy E; Piperno M; Auroux M; Kostine M; Maillet D; Amini-Adle M; Fabien N; Estublier C; Goncalves D; Girard N; Confavreux CB
    Bull Cancer; 2021 Jun; 108(6):643-653. PubMed ID: 33902919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature.
    Cappelli LC; Gutierrez AK; Bingham CO; Shah AA
    Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1751-1763. PubMed ID: 27998041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
    Cappelli LC; Bingham CO
    Arthritis Rheumatol; 2021 Apr; 73(4):553-565. PubMed ID: 33186490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
    Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T
    Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of rheumatic adverse events of cancer immunotherapy.
    Reid P; Cappelli LC
    Best Pract Res Clin Rheumatol; 2022 Dec; 36(4):101805. PubMed ID: 36539321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
    Leipe J; Mariette X
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.
    Kostine M; Rouxel L; Barnetche T; Veillon R; Martin F; Dutriaux C; Dousset L; Pham-Ledard A; Prey S; Beylot-Barry M; Daste A; Gross-Goupil M; Lallier J; Ravaud A; Forcade E; Bannwarth B; Truchetet ME; Richez C; Mehsen N; Schaeverbeke T;
    Ann Rheum Dis; 2018 Mar; 77(3):393-398. PubMed ID: 29146737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events.
    Ladouceur A; Ezdoglian A; Sparks JA; Hudson M; Jamal S; Clifford A; Roberts J; Ye C
    Rheum Dis Clin North Am; 2024 May; 50(2):181-199. PubMed ID: 38670720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations.
    Casagrande S; Sopetto GB; Bertalot G; Bortolotti R; Racanelli V; Caffo O; Giometto B; Berti A; Veccia A
    Cancers (Basel); 2024 Apr; 16(7):. PubMed ID: 38611115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rheumatic Complications of Immune Checkpoint Inhibitors.
    Ghosh N; Bass AR
    Rheum Dis Clin North Am; 2022 May; 48(2):411-428. PubMed ID: 35400368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity.
    Calabrese C; Kirchner E; Kontzias A; Velcheti V; Calabrese LH
    RMD Open; 2017; 3(1):e000412. PubMed ID: 28405474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.
    Mooradian MJ; Nasrallah M; Gainor JF; Reynolds KL; Cohen JV; Lawrence DP; Miloslavsky EM; Kohler MJ; Sullivan RJ; Schoenfeld SR
    Semin Arthritis Rheum; 2019 Jun; 48(6):1127-1132. PubMed ID: 30409415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.
    Melissaropoulos K; Klavdianou K; Filippopoulou A; Kalofonou F; Kalofonos H; Daoussis D
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32403289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
    Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
    Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors.
    Zeng L; Ma G; Chen K; Zhou Q
    Front Immunol; 2023; 14():1242336. PubMed ID: 37869006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheumatic Complications of Immune Checkpoint Inhibitors.
    Ghosh N; Bass AR
    Med Clin North Am; 2021 Mar; 105(2):227-245. PubMed ID: 33589099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group.
    Ghosh N; Couette N; van Binsbergen WH; Weinmann SC; Jivanelli B; Shea B; Bass AR; Benesova K; Bingham CO; Calabrese C; Cappelli LC; Chan KK; Choy E; Daoussis D; Goodman S; Hudson M; Jamal S; Leipe J; Lopez-Olivo MA; Suarez-Almazor M; van der Laken CJ; Meara AS; Liew D; Kostine M
    Semin Arthritis Rheum; 2023 Feb; 58():152110. PubMed ID: 36372016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.